B+
Bull case
25%
Probability
Target price
$210.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
DVA
DaVitaBNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
Current thesis
The Q2 print supports a constructive operating case: EPS was $4.02, operating margin improved sequentially, free cash flow remained strong, and repurchases continued. Sustained reimbursement, volume, and cost execution could support a recovery toward the packet's $230 median target.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +3.6.
What can break
Current analyst revisions and a robust public peer valuation set are unavailable; only Fresenius Medical Care is a clear direct public operating peer.
Momentum
7
Value
70
Sentiment
67
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $192.00 · Bull $210.00 · Bear $160.00Analysis 2026-08-07; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-07 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $227.33
Why
Momentum7 · Δ7d +1.6
Value70 · Δ7d -0.0
Sentiment67 · Δ7d +3.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +3.6.
Contradictions & invalidation
- • Current analyst revisions and a robust public peer valuation set are unavailable; only Fresenius Medical Care is a clear direct public operating peer.
- • Normalized non-acquired treatment growth remains low, limiting organic volume visibility.
- • The market response was not clearly supportive, normalized non-acquired treatment growth remained only 0.3% year over year, revenue per treatment declined sequentially, and the company added $500 million of term debt.
Catalyst clock
2026-08-04
Q2 results showed stronger margins and cash generation, but mature underlying volume
Lead driver: Sentiment · See AI snapshot
Momentum
7
9% active weight
Current posture
7d trendImproving
Δ7d
+1.6
Δ21d
-11.2
Value
70
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.4
Sentiment
67
62% active weight
Current posture
7d trendImproving
Δ7d
+3.6
Δ21d
+0.4
Why this grade
Composite grade B. Momentum 7.3 / Value 69.9 / Sentiment 67.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-07. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$192.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$160.00
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$11.27B
Beta
0.99
Shares Out
63.8M
P/E (TTM)
11.7
P/S (TTM)
0.60
P/FCF (TTM)
6.22
Rev YoY
+5.2%
EPS YoY
+55.8%
Gross Margin
+27.3%
Op Margin
+14.9%
Net Debt
$12.29B
Current Ratio
1.47
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data